CA03835T3091 - Common Stock
APTO stock results show that Aptose Biosciences beat analyst estimates for earnings per share the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Aptose Biosciences (NASDAQ:APTO) just reported results for the fourth quarter o...
Aptose Reports Results for the Fourth Quarter and Full Year 2023 ...
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024 ...
Aptose closes previously announced public offering and private placement...
Levi Strauss layoffs are coming for as much as 15% of its corporate workforce as it prepares for a rough economy in 2024!
SU Group stock volatile on Friday following the company's IPO earlier this week with shares currently trading below its debut price.
Aptose Biosciences stock is sliding lower on Friday as investors react to a public offering and private placement for APTO shares.
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical ...
Pre-market stock movers are worth checking out on Friday as we get into all of the biggest news affecting shares this morning!
ASH Oral Presentation: Complete Response Data from the Ongoing APTIVATE Phase 1/2 Study of Tuspetinib (TUS) in R/R AML Patients...
Aptose Biosciences (APTO) Friday filed a prospectus related to the proposed sale of its 4.09M ordinary shares and pre-funded warrants. This prospectus is not an
Aptose Reports Results for the Third Quarter 2023 • TUS/VEN Therapy Active in R/R VEN Failure AML Patients – Guides Toward Accelerated Approval Path...
Data from the Ongoing APTIVATE International Phase 1/2 Study in Relapsed/Refractory AML Patients
Aptose Presents Latest Available Data on AML Drug Tuspetinib - 48% ORR with TUS/VEN in Heavily Pre-treated R/R AML Patients ...
Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023 ...
Aptose to Hold Clinical Update Webcast and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th ...
Company to Hold Clinical Update Webcast; Details Forthcoming
Aptose to present TUS/VEN AML data at ESH; to hold clinical update webcast on October 30th. TUS appears to re-sensitize Prior-VEN failure patients to...
SAN DIEGO and TORONTO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage...
— TUS/VEN doublet continues safe and effective in AML patients who failed prior venetoclax —...